Pioneering better science through the 3Rs: An introduction to the National Centre for the Replacement, Refinement, and Reduction of Animals in Research (NC3Rs)

Journal of the American Association for Laboratory Animal Science

Volumn 54, Issue 2, 2015, Pages 198-208

  Burden, Natalie ^a   Chapman, Kathryn ^a   Sewell, Fiona ^a   Robinson, Vicky ^a  

^a National Centre for the Replacement   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY;

ANIMAL TESTING REDUCTION; ANIMAL TESTING REFINEMENT; ANIMAL TESTING REPLACEMENT; ARTICLE; ASTHMA; EXPERIMENTAL ANIMAL WELFARE; MEDICAL RESEARCH; NONHUMAN; POLICY; UNITED KINGDOM; ANIMAL; ANIMAL EXPERIMENT; ANIMAL WELFARE; COOPERATION; DISEASE MODEL; DRUG INDUSTRY; GREAT BRITAIN; PRIMATE;

ANIMALIA; PRIMATES;

ANIMAL EXPERIMENTATION; ANIMAL WELFARE; ANIMALS; ASTHMA; COOPERATIVE BEHAVIOR; DISEASE MODELS, ANIMAL; DRUG INDUSTRY; GREAT BRITAIN; PRIMATES;

EID: 84926666021     PISSN: 15596109     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Beaumont K, Gardner I, Chapman K, Hall M, Rowland M. 2011. Toward an integrated human clearance prediction strategy that minimizes animal use. J Pharm Sci 100:4518-4535.
2. Buckley LA, Chapman K, Burns-Naas LA, Todd MD, Martin PL, Lansita JA. 2011. Considerations regarding nonhuman primate use in safety assessment of biopharmaceuticals. Int J Toxicol 30:583-590.
3. Chapman K, Chivers S, Gliddon D, Mitchell D, Robinson S, Sangster T, Sparrow S, Spooner N, Wilson A. 2014. Overcoming the barriers to the uptake of nonclinical microsampling in regulatory safety studies. Drug Discov Today 19:528-32.
4. Chapman K, Pullen N, Coney L, Dempster M, Andrews L, Bajramovic J, Baldrick P, Buckley L, Jacobs A, Hale G, Green C, Ragan I, Robinson V. 2009. Preclinical development of monoclonal antibodies: considerations for the use of nonhuman primates. MAbs 1:505-516.
5. Chapman K, Pullen N, Graham M, Ragan I. 2007. Preclinical safety testing of monoclonal antibodies: the significance of species relevance. Nat Rev Drug Discov 6:120-126.
6. Chapman K, Sewell F, Allais L, Delongeas JL, Donald E, Festag M, Kervyn S, Ockert D, Nogues V, Palmer H, Popovic M, Roosen W, Schoenmakers A, Somers K, Stark C, Stei P, Robinson S. 2013. A global pharmaceutical company initiative: an evidence-based approach to define the upper limit of body weight loss in short-term toxicity studies. Regul Toxicol Pharmacol 67:27-38.
7. Chapman KL, Andrews L, Bajramovic JJ, Baldrick P, Black LE, Bowman CJ, Buckley LA, Coney LA, Couch J, Maggie Dempster A, de Haan L, Jones K, Pullen N, de Boer AS, Sims J, Ian Ragan C. 2012. The design of chronic toxicology studies of monoclonal antibodies: implications for the reduction in use of nonhuman primates. Regul Toxicol Pharmacol 62:347-354.
8. Chapman KL, Holzgrefe H, Black LE, Brown M, Chellman G, Copeman C, Couch J, Creton S, Gehen S, Hoberman A, Kinter LB, Madden S, Mattis C, Stemple HA, Wilson S. 2013. Pharmaceutical toxicology: designing studies to reduce animal use while maximizing human translation. Regul Toxicol Pharmacol 66:88-103.
9. Chapman KL, Pullen N, Andrews L, Ragan I. 2010. The future of nonhuman primate use in mAbs development. Drug Discov Today 15:235-242.
10. Creton S, Aardema MJ, Carmichael PL, Harvey JS, Martin FL, Newbold RF, O'Donovan MR, Pant K, Poth A, Sakai A, Sasaki K, Scott AD, Schechtman LM, Shen RR, Tanaka N, Yasaei H. 2012. Cell transformation assays for prediction of carcinogenic potential: state of the science and future research needs. Mutagenesis 27:93-101.
11. Creton S, Billington R, Davies W, Dent MP, Hawksworth GM, Parry S, Travis KZ. 2009. Application of toxicokinetics to improve chemical risk assessment: implications for the use of animals. Regul Toxicol Pharmacol 55:291-299.
12. Creton S, Clook M, Wheeler JR. 2014. Application of the threshold approach for acute fish toxicity testing to plant protection products: a proposed framework. Chemosphere 96:195-200.
13. Creton S, Dewhurst IC, Earl LK, Gehen SC, Guest RL, Hotchkiss JA, Indans I, Woolhiser MR, Billington R. 2010. Acute toxicity testing of chemicals - opportunities to avoid redundant testing and use alternative approaches. Crit Rev Toxicol 40:50-83.
14. Creton S, Douglas M, Wheeler JR, Hutchinson TH. 2010. Challenging the requirement for chronic fish toxicity studies on formulated plant protection products. Toxicol Lett 199:111-114.
15. Creton S, Saghir SA, Bartels MJ, Billington R, Bus JS, Davies W, Dent MP, Hawksworth GM, Parry S, Travis KZ. 2012. Use of toxicokinetics to support chemical evaluation: informing high-dose selection and study interpretation. Regul Toxicol Pharmacol 62:241-247.
16. Creton S, Weltje L, Hobson H, Wheeler JR. 2013. Reducing the number of fish in bioconcentration studies for plant protection products by reducing the number of test concentrations. Chemosphere 90:1300-1304.
17. Hay M, Thomas DW, Craighead JL, Economides C, Rosenthal J. 2014. Clinical development success rates for investigational drugs. Nat Biotechnol 32:40-51.
18. Holmes A, Brown R, Shakesheff K. 2009. Engineering tissue alternatives to animals: applying tissue engineering to basic research and safety testing. Regen Med 4:579-592.
19. Holmes AM, Rudd JA, Tattersall FD, Aziz Q, Andrews PL. 2009. Opportunities for the replacement of animals in the study of nausea and vomiting. Br J Pharmacol 157:865-880.
20. Holmes AM, Solari R, Holgate ST. 2011. Animal models of asthma: value, limitations, and opportunities for alternative approaches. Drug Discov Today 16:659-670.
21. Jennings M, Prescott MJ, Buchanan-Smith HM, Gamble MR, Gore M, Hawkins P, Hubrecht R, Hudson S, Keeley JR, Morris K, Morton DB, Owen S, Pearce PC, Robb D, Rumble RJ, Wolfensohn S, Buist D. 2009. Refinements in husbandry, care, and common procedures for nonhuman primates: 9th report of the BVAAWF/FRAME/RSPCA/UFAW Joint Working Group on Refinement. Lab Anim 43 Suppl 1:1-47.
22. Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG. 2010. Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol 8:e1000412.
23. Kola I, Landis J. 2004. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 3:711-715.
24. Lave T, Chapman K, Goldsmith P, Rowland M. 2009. Human clearance prediction: shifting the paradigm. Expert Opin Drug Metab Toxicol 5:1039-1048.
25. O'Connor EC, Chapman K, Butler P, Mead AN. 2011. The predictive validity of the rat self-administration model for abuse liability. Neurosci Biobehav Rev 35:912-938.
26. Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, Lindborg SR, Schacht AL. 2010. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat Rev Drug Discov 9:203-214.
27. Percie du Sert N. 2011. Improving the reporting of animal research: when will we ARRIVE? Dis Model Mech 4:281-282.
28. Percie du Sert N. 2011. Systematic review and meta-analysis of preclinical research: the need for reporting guidelines. Eur Heart J 32:2340.
29. Percie du Sert N. 2012. Maximising the output of osteoarthritis research: the ARRIVE guidelines. Osteoarthritis Cartilage 20:253-255.
30. Percie du Sert N, Holmes AM, Wallis R, Andrews PL. 2012. Predicting the emetic liability of novel chemical entities: a comparative study. Br J Pharmacol 165:1848-1867.
31. Prescott MJ, Brown VJ, Flecknell PA, Gaffan D, Garrod K, Lemon RN, Parker AJ, Ryder K, Schultz W, Scott L, Watson J, Whitfield L. 2010. Refinement of the use of food and fluid control as motivational tools for macaques used in behavioural neuroscience research: report of a Working Group of the The NC3Rs. J Neurosci Methods 193:167-188.
32. Prescott MJ, Buchanan-Smith HM. 2003. Training nonhuman primates using positive reinforcement techniques. J Appl Anim Welf Sci 6:157-161.
33. Price C, Stallard N, Creton S, Indans I, Guest R, Griffiths D, Edwards P. 2011. A statistical evaluation of the effects of gender differences in assessment of acute inhalation toxicity. Hum Exp Toxicol 30:217-238.
34. Redfern WS, Armstrong JD, Heward J, Allison B, Lukins T, Grant C, Leslie L, Craig DJ, Vickers C, Champman K. 2014. Rodent Big Brother: development and validation of a home cage automated behavioural monitoring system for use in repeat-dose toxicity studies in rats. Toxicol Lett 229:S47-S48.
35. Robinson S, Delongeas JL, Donald E, Dreher D, Festag M, Kervyn S, Lampo A, Nahas K, Nogues V, Ockert D, Quinn K, Old S, Pickersgill N, Somers K, Stark C, Stei P, Waterson L, Chapman K. 2008. A European pharmaceutical company initiative challenging the regulatory requirement for acute toxicity studies in pharmaceutical drug development. RTP 50:345-352.
36. Robinson V. 2009. Less is more: reducing the reliance on animal models for nausea and vomiting research. Br J Pharmacol 157:863-864.
37. Sewell F, Chapman K, Baldrick P, Brewster D, Broadmeadow A, Brown P, Burns-Naas LA, Clarke J, Constan A, Couch J, Czupalla O, Danks A, DeGeorge J, de Haan L, Hettinger K, Hill M, Festag M, Jacobs A, Jacobson-Kram D, Kopytek S, Lorenz H, Moesgaard SG, Moore E, Pasanen M, Perry R, Ragan I, Robinson S, Schmitt PM, Short B, Lima BS, Smith D, Sparrow S, van Bekkum Y, Jones D. 2014. Recommendations from a global cross-company data sharing initiative on the incorporation of recovery phase animals in safety assessment studies to support first-in-human clinical trials. Regul Toxicol Pharmacol 70:413-429.
38. Stallard N, Price C, Creton S, Indans I, Guest R, Griffiths D, Edwards P. 2011. A new sighting study for the fixed concentration procedure to allow for gender differences. Hum Exp Toxicol 30:239-249.
39. Sun T, Swindle EJ, Collins JE, Holloway JA, Davies DE, Morgan H. 2010. On-chip epithelial barrier function assays using electrical impedance spectroscopy. Lab Chip 10:1611-1617.
40. Swallow J, Anderson D, Buckwell AC, Harris T, Hawkins P, Kirkwood J, Lomas M, Meacham S, Peters A, Prescott M, Owen S, Quest R, Sutcliffe R, Thompson K. 2005. Guidance on the transport of laboratory animals. Lab Anim 39:1-39.
41. Westmoreland C, Holmes AM. 2009. Assuring consumer safety without animals: applications for tissue engineering. Organogenesis 5:67-72.